

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

SECTION 1. IDENTIFICATION

Product identifier : Levamisole / Oxfendazole Formulation

Other means of identification : Scanda (A007130)

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Acute toxicity (Oral) : Category 5

Reproductive toxicity : Category 1B

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 2

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.
H360FD May damage fertility. May damage the unborn child.
H400 Very toxic to aquatic life.
H411 Toxic to aquatic life with long lasting effects.

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808164-00007 Date of last issue: 28.09.2024
Date of first issue: 05.07.2022

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P301 + P312 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:
P405 Store locked up.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Levamisole hydrochloride	16595-80-5	Acute Tox. (Oral), 3 Repr., 2 STOT RE, (Oral)(Blood, Testis) , 2 Aquatic Acute, 3 Aquatic Chronic, 3	≥ 5 -< 10
oxfendazole	53716-50-0	Repr., 1B STOT RE, (Liver, Testis) , 2 Aquatic Acute, 1 Aquatic Chronic, 1	$\geq 2,5$ -< 5
Polyethylene glycol stearate	9004-99-3		≥ 1 -< 5
Citric acid	77-92-9	Eye Irrit., 2A STOT SE, 3	≥ 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

		of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May be harmful if swallowed. May damage fertility. May damage the unborn child.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers).

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808164-00007 Date of last issue: 28.09.2024
 Date of first issue: 05.07.2022

Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	200 µg/100 cm ²	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Polyethylene glycol stearate	9004-99-3	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	:	Aqueous solution
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
------------------------------------------	---	--------------------------------------------------------

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 2.250 mg/kg Method: Calculation method
---------------------	---	--------------------------------------------------------------------

Components:**Levamisole hydrochloride:**

Acute oral toxicity	:	LD50 (Rat): 180 mg/kg LD50 (Mouse): 223 mg/kg LD50 (Rabbit): 458 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available

oxfendazole:

Acute oral toxicity	:	LD50 (Rat): > 6.000 mg/kg LD50 (Dog): 1.600 mg/kg
---------------------	---	------------------------------------------------------

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

LD50 (sheep): 250 mg/kg

Polyethylene glycol stearate:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Remarks : No data available

oxfendazole:

Species : Rabbit
Result : No skin irritation

Polyethylene glycol stearate:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Remarks : No data available

oxfendazole:

Species : Rabbit
Result : No eye irritation

Polyethylene glycol stearate:

Species : Rabbit

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Result	: No eye irritation
Method	: Draize Test

Citric acid:

Species	: Rabbit
Result	: Irritation to eyes, reversing within 21 days
Method	: OECD Test Guideline 405

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Remarks	: No data available
---------	---------------------

Polyethylene glycol stearate:

Test Type	: Open epicutaneous test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	: Test Type: Chromosome aberration test in vitro Result: negative

oxfendazole:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive

Polyethylene glycol stearate:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--------------------------------------------------------------------------

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

II

Citric acid:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: in vitro micronucleus test Result: positive
		Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	80 mg/kg body weight
Remarks	:	No significant adverse effects were reported

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

oxfendazole:

Species	:	Rat
Application Route	:	Oral
Exposure time	:	1 Years
Symptoms	:	No adverse effects.
Target Organs	:	Liver

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Symptoms	:	No adverse effects.
Target Organs	:	Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Components:**Levamisole hydrochloride:**

- | | | |
|------------------------------------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effects on fertility | : | Test Type: Three-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Result: No significant adverse effects were reported |
| Effects on fetal development | : | Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: Fetotoxicity.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity. |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments. |

oxfendazole:

- | | | |
|------------------------------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effects on fertility | : | Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 17 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0,9 mg/kg body weight
Target Organs: Liver
Result: No effects on fertility.

Test Type: Fertility
Species: Mouse
Application Route: Oral
Duration of Single Treatment: 1 Months
Fertility: NOAEL: 750 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility. |
| Effects on fetal development | : | Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: positive, Fetal effects.

Test Type: Embryo-fetal development
Species: Rat |

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: positive, Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 108 mg/kg body weight
Result: positive, Embryo-fetal toxicity., Fetal abnormalities.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 0,625 mg/kg body weight

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

Components:**Citric acid:**

Assessment : May cause respiratory irritation.

STOT-repeated exposure

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Target Organs : Blood, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Routes of exposure : Oral
Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Repeated dose toxicity**Components:****Levamisole hydrochloride:**

Species	: Rat
NOAEL	: 2,5 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Testis

Species	: Dog
LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Blood

Species	: Dog
LOAEL	: 40 mg/kg
Application Route	: Oral
Exposure time	: 3 Months

oxfendazole:

Species	: Rat
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis

Species	: Rat
NOAEL	: 3,8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis

Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver

Species	: Mouse
NOAEL	: 37,5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver

Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 11 mg/kg

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland

Species	: Dog
NOAEL	: 13,5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

Citric acid:

Species	: Rat
NOAEL	: 4.000 mg/kg
LOAEL	: 8.000 mg/kg
Application Route	: Ingestion
Exposure time	: 10 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Levamisole hydrochloride:**

Ingestion	: Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension
-----------	----------------------------------------------------------------

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Levamisole hydrochloride:**

Toxicity to fish	: LC50 (<i>Oryzias latipes</i> (Japanese medaka)): 37,3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (<i>Daphnia magna</i> (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202

oxfendazole:

Toxicity to fish	: LC50 (<i>Lepomis macrochirus</i> (Bluegill sunfish)): > 2,7 mg/l Exposure time: 96 h LC50 (<i>Oncorhynchus mykiss</i> (rainbow trout)): > 2,5 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (<i>Daphnia magna</i> (Water flea)): 0,059 mg/l Exposure time: 48 h Method: OECD Test Guideline 202

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	10
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0,023 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	1

Polyethylene glycol stearate:

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 10.000 mg/l Exposure time: 96 h Method: DIN 38412
Toxicity to microorganisms	:	EC10 (Bacteria): > 10.000 mg/l Exposure time: 16 h

Citric acid:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1.535 mg/l Exposure time: 24 h

Persistence and degradability**Components:****oxfendazole:**

Stability in water	:	Hydrolysis: < 5 % (4 d)
--------------------	---	-------------------------

Polyethylene glycol stearate:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: > 70 % Exposure time: 10 d Method: OECD Test Guideline 302B
------------------	---	---------------------------------------------------------------------------------------------------------------------

Citric acid:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 97 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	-------------------------------------------------------------------------------------------------------------------

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

II

Bioaccumulative potential**Components:****oxfendazole:**

Partition coefficient: n-octanol/water	: log Pow: 1,95
----------------------------------------	-----------------

Citric acid:

Partition coefficient: n-octanol/water	: log Pow: -1,72
----------------------------------------	------------------

Mobility in soil**Components:****oxfendazole:**

Distribution among environmental compartments	: log Koc: 3,2
-----------------------------------------------	----------------

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)
Class	: 9
Packing group	: III
Labels	: 9
Environmentally hazardous	: yes

IATA-DGR

UN/ID No.	: UN 3082
Proper shipping name	: Environmentally hazardous substance, liquid, n.o.s. (oxfendazole)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 964

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)
Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

Revision Date : 14.04.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10808164-00007	Date of first issue: 05.07.2022

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8